Newtyn Capital Partners, LP is Director at MERRIMACK PHARMACEUTICALS INC (MACK). They have made 6 open-market trades across 2 companies since 2020, most recently 2022-06-17.
CIK 0001789643
5 open-market purchases totalling $2.2M since 2020, against 1 sale. Across 5 scored buys the stock is up 10.7% at ninety days, and 1.4 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 60% | 40% |
| Avg Move | -2.6% | +14.2% | +10.7% |
| Alpha | -6.2% | +10.0% | +1.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MACK | BUY | 2022-06-16 | 2022-06-21 | $5.78 | $8K | -6.1% | -6.3% | -35.1% |
| GTX | BUY | 2021-01-04 | 2021-01-11 | $4.61 | $1.6M | -5.4% | -5.9% | -5.9% |
| GTX | SELL | 2021-01-04 | 2021-01-11 | $4.40 | $529K | -5.4% | -5.9% | -5.9% |
| MACK | BUY | 2020-11-12 | 2020-11-16 | $3.65 | $412K | -2.8% | +75.9% | +97.7% |
| MACK | BUY | 2020-08-11 | 2020-08-13 | $3.45 | $55K | +15.0% | +6.9% | +3.9% |
| MACK | BUY | 2020-04-03 | 2020-04-07 | $2.74 | $46K | -13.5% | +0.5% | -6.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.